Treating CGL: Standard Care and Medications
At a Glance
Treatment for congenital generalized lipodystrophy combines an individualized diet that supports growth with metreleptin when prescribed, medicines for insulin resistance and high triglycerides, and lifelong monitoring by a specialist team.
Managing Congenital Generalized Lipodystrophy (CGL) requires a comprehensive, lifelong strategy. Because CGL affects nearly every system in the body, treatment focuses on preventing and controlling metabolic complications like diabetes, high triglycerides, and liver disease [1][2]. The goal is to “mimic” the functions that healthy fat cells usually perform.
The Foundation: Dietary Management
Diet is the most critical everyday tool for managing CGL. Because your child cannot store fat safely, the fat they eat must be managed carefully to prevent it from building up in the blood and organs [1][3]. However, children still need adequate energy, essential fatty acids, and fat-soluble vitamins for growth; never impose a very-low-fat or calorie-restricted diet without a metabolic dietitian’s individualized plan.
- Individualized Approach: A tailored dietary plan is required to keep triglycerides (blood fats) at safe levels while accommodating age and growth requirements [4].
- Limiting “Fast Sugars”: Reducing simple sugars and refined carbohydrates helps manage severe insulin resistance and prevents sharp spikes in blood glucose [4][5].
- Ensuring Growth: It is vital to work with a metabolic dietitian. They will help ensure your child gets enough calories and essential nutrients to grow properly while keeping their metabolic numbers stable [1][6].
Metreleptin: Leptin Replacement Therapy
Metreleptin (Myalept) is a specialized medication approved in many countries to treat the complications of generalized lipodystrophy [7]. It is a man-made version of the hormone leptin, which children with CGL lack [1].
- How it Works: By replacing leptin, this treatment can significantly reduce the intense hunger (hyperphagia) your child experiences. It also helps the liver process fat better and improves how the body responds to insulin [8][9]. It is not a cure and does not replace diet and surveillance.
- Administration: Metreleptin is given as a daily subcutaneous (under the skin) injection. The dose is carefully calculated based on your child’s weight and is adjusted as they grow [8].
- Important Monitoring:
- Hypoglycemia Risk: Because metreleptin makes the body much more sensitive to insulin, any existing insulin doses may need to be reduced when starting therapy to prevent dangerously low blood sugar (hypoglycemia) [8][10]. Never start, stop, or dose-adjust insulin without the prescribing team.
- Antibodies: Some patients develop neutralizing antibodies to the medication, which can cause a loss of metabolic benefit or lead to severe infections. Your doctor will monitor your child’s numbers closely [11][12].
- T-Cell Lymphoma: There have been very rare reports of T-cell lymphoma in patients with lipodystrophy. While the causal role of the drug remains uncertain, doctors monitor all patients as a precaution [13][14].
Conventional Medications
In addition to diet and metreleptin, other standard medications are used to target specific symptoms. Over-the-counter supplements are not interchangeable with prescribed formulas.
- For Insulin Resistance: Metformin is commonly used to help the body use insulin more effectively [1][15].
- For High Triglycerides: Fibrates or highly concentrated prescription fish oils may be prescribed to lower the amount of fat in the blood and reduce the risk of pancreatitis [1][15].
- For High Cholesterol: Statins may be used if other cholesterol markers (like LDL) are high [1].
What to Avoid: Contraindications
Certain treatments common for other conditions can be harmful to children with CGL:
- Oral Estrogens: These are generally avoided because they can cause a massive, dangerous spike in triglyceride levels, increasing the risk of life-threatening pancreatitis [1]. However, contraception and puberty decisions require individualized review; never stop a prescribed hormone without medical advice, as the route of administration matters.
Your Multidisciplinary Care Team
CGL is too complex for any one doctor to manage alone. Standard care involves a team of specialists who meet at least annually to screen for heart, liver, and kidney complications [1][2].
- Pediatric Endocrinologist: Manages diabetes, insulin resistance, and metreleptin.
- Hepatologist: Monitors liver health and fat buildup.
- Cardiologist: Performs regular EKGs and echos, especially critical for CGL4 and CGL2.
- Metabolic Dietitian: Creates the essential meal plans.
- Psychosocial Support: Counselors can help your family navigate the emotional challenges of a chronic rare disease [6].
Common questions in this guide
What diet is recommended for a child with congenital generalized lipodystrophy?
How can metreleptin help a child with CGL?
Why might insulin doses change after starting metreleptin?
What safety monitoring is needed during metreleptin treatment?
Which medicines may be used for CGL complications?
Are oral estrogens safe for children with CGL?
Why does CGL care require several specialists?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Who is the lead 'navigator' for our multidisciplinary team, and does it include a pediatric endocrinologist and a specialized metabolic dietitian?
- 2.How should we adjust my child's insulin or metformin doses if we start metreleptin therapy to avoid low blood sugar (hypoglycemia)?
- 3.What is our specific target for my child's triglyceride levels to reduce the risk of pancreatitis?
- 4.Can you help us design a low-fat meal plan that provides enough energy for my child's growth while managing their intense hunger (hyperphagia)?
- 5.Are there specific 'red flag' symptoms I should watch for that might indicate my child is developing an allergy or neutralizing antibodies to their medication?
- 6.How often will we screen my child's liver, kidneys, and heart to monitor for potential long-term complications?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (15)
- 1
The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.
Brown RJ, Araujo-Vilar D, Cheung PT, et al.
The Journal of clinical endocrinology and metabolism 2016; (101(12)):4500-4511 doi:10.1210/jc.2016-2466.
PMID: 27710244 - 2
Diagnosis, treatment and management of lipodystrophy: the physician perspective on the patient journey.
Patni N, Chard C, Araújo-Vilar D, et al.
Orphanet journal of rare diseases 2024; (19(1)):263 doi:10.1186/s13023-024-03245-3.
PMID: 38992753 - 3
Monogenic forms of lipodystrophic syndromes: diagnosis, detection, and practical management considerations from clinical cases.
Vatier C, Vantyghem MC, Storey C, et al.
Current medical research and opinion 2019; (35(3)):543-552 doi:10.1080/03007995.2018.1533459.
PMID: 30296183 - 4
Clinical outcome in a series of pediatric patients with congenital generalized lipodystrophies treated with dietary therapy.
Papendieck L, Araujo MB
Journal of pediatric endocrinology & metabolism : JPEM 2018; (31(1)):77-83 doi:10.1515/jpem-2017-0355.
PMID: 29267171 - 5
Is it possible to achieve an acceptable disease control by dietary therapy alone in Berardinelli Seip type 1? Experience from a case report.
Cecchetti C, Belardinelli E, Dionese P, et al.
Frontiers in endocrinology 2023; (14()):1190363 doi:10.3389/fendo.2023.1190363.
PMID: 37347108 - 6
The long-term management of congenital generalized lipodystrophy (Berardinelli-Seip syndrome): the clinical manifestations of Japanese siblings for approximately 20 years.
Maeda M, Maeda T, Ebihara K, Ihara K
Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology 2019; (28(4)):139-145 doi:10.1297/cpe.28.139.
PMID: 31666767 - 7
Diagnosis and treatment of lipodystrophy: a step-by-step approach.
Araújo-Vilar D, Santini F
Journal of endocrinological investigation 2019; (42(1)):61-73 doi:10.1007/s40618-018-0887-z.
PMID: 29704234 - 8
Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy.
Brown RJ, Oral EA, Cochran E, et al.
Endocrine 2018; (60(3)):479-489 doi:10.1007/s12020-018-1589-1.
PMID: 29644599 - 9
Update on Therapeutic Options in Lipodystrophy.
Akinci B, Meral R, Oral EA
Current diabetes reports 2018; (18(12)):139 doi:10.1007/s11892-018-1100-7.
PMID: 30370487 - 10
Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program.
Ajluni N, Dar M, Xu J, et al.
Journal of diabetes & metabolism 2016; (7(3)).
PMID: 27642538 - 11
Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.
Chan JL, Koda J, Heilig JS, et al.
Clinical endocrinology 2016; (85(1)):137-49 doi:10.1111/cen.12980.
PMID: 26589105 - 12
Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report.
Takeyari S, Takakuwa S, Miyata K, et al.
Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology 2019; (28(1)):1-7 doi:10.1297/cpe.28.1.
PMID: 30745727 - 13
A real-world pharmacovigilance assessment and literature review of lymphoma development in lipodystrophy.
Brown RJ, Araujo-Vilar D, Walkovich KJ, et al.
Frontiers in endocrinology 2025; (16()):1582715 doi:10.3389/fendo.2025.1582715.
PMID: 40469440 - 14
Lymphoma in acquired generalized lipodystrophy.
Brown RJ, Chan JL, Jaffe ES, et al.
Leukemia & lymphoma 2016; (57(1)):45-50 doi:10.3109/10428194.2015.1040015.
PMID: 25864863 - 15
Lipodystrophy for the Diabetologist-What to Look For.
Patni N, Garg A
Current diabetes reports 2022; (22(9)):461-470 doi:10.1007/s11892-022-01485-w.
PMID: 35821558
This page is for informational purposes only and does not constitute medical advice. Your child's pediatric endocrinology team and metabolic dietitian should tailor diet, medicines, and monitoring to their needs.
Get notified when new evidence is published on Congenital generalized lipodystrophy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.